|
1
|
Anwanwan D, Singh SK, Singh S, Saikam V
and Singh R: Challenges in liver cancer and possible treatment
approaches. Biochim Biophys Acta Rev Cancer. 1873:1883142020.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shi JF, Cao M, Wang Y, Bai FZ, Lei L, Peng
J, Feletto E, Canfell K, Qu C and Chen W: Is it possible to halve
the incidence of liver cancer in China by 2050? Int J Cancer.
148:1051–1065. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fu J and Wang H: Precision diagnosis and
treatment of liver cancer in China. Cancer Lett. 412:283–288. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Villanueva A: Hepatocellular Carcinoma. N
Engl J Med. 380:1450–1462. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang H, Lu Z and Zhao X: Tumorigenesis,
diagnosis, and therapeutic potential of exosomes in liver cancer. J
Hematol Oncol. 12:1332019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fulgenzi CAM, Talbot T, Murray SM,
Silletta M, Vincenzi B, Cortellini A and Pinato DJ: Immunotherapy
in hepatocellular carcinoma. Curr Treat Options Oncol. 22:872021.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eferl R and Trauner M: Chromosomal
instability in HCC: A key function for checkpoint kinase 2. Gut.
67:204–205. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sudakin V, Chan GK and Yen TJ: Checkpoint
inhibition of the APC/C in HeLa cells is mediated by a complex of
BUBR1, BUB3, CDC20, and MAD2. J Cell Biol. 154:925–936. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vodermaier HC, Gieffers C, Maurer-Stroh S,
Eisenhaber F and Peters JM: TPR subunits of the anaphase-promoting
complex mediate binding to the activator protein CDH1. Curr Biol.
13:1459–1468. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ishida H, Miwa H, Tatsuta M, Masutani S,
Imamura H, Shimizu J, Ezumi K, Kato H, Kawasaki T, Furukawa H and
Kawakami H: Ki-67 and CEA expression as prognostic markers in
Dukes' C colorectal cancer. Cancer Lett. 207:109–115. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Melloy PG: The anaphase-promoting complex:
A key mitotic regulator associated with somatic mutations occurring
in cancer. Genes Chromosomes Cancer. 59:189–202. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
VanGenderen C, Harkness TAA and Arnason
TG: The role of anaphase promoting complex activation, inhibition
and substrates in cancer development and progression. Aging (Albany
NY). 12:15818–15855. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li J, Gao JZ, Du JL, Huang ZX and Wei LX:
Increased CDC20 expression is associated with development and
progression of hepatocellular carcinoma. Int J Oncol. 45:1547–1555.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao Y, Tang Q, Ni R, Huang X, Wang Y, Lu
C, Shen A, Wang Y, Li C, Yuan Q, et al: Early mitotic inhibitor-1,
an anaphase-promoting complex/cyclosome inhibitor, can control
tumor cell proliferation in hepatocellular carcinoma: Correlation
with Skp2 stability and degradation of p27(Kip1). Hum Pathol.
44:365–373. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Prinz S, Hwang ES, Visintin R and Amon A:
The regulation of Cdc20 proteolysis reveals a role for APC
components Cdc23 and Cdc27 during S phase and early mitosis. Curr
Biol. 8:750–760. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hershko A: Mechanisms and regulation of
the degradation of cyclin B. Philos Trans R Soc Lond B Biol Sci.
354:1571–1575. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thomas C, Wetherall B, Levasseur MD,
Harris RJ, Kerridge ST, Higgins JMG, Davies OR and Madgwick S: A
prometaphase mechanism of securin destruction is essential for
meiotic progression in mouse oocytes. Nat Commun. 12:43222021.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zachariae W and Nasmyth K: TPR proteins
required for anaphase progression mediate ubiquitination of mitotic
B-type cyclins in yeast. Mol Biol Cell. 7:791–801. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang L, Rahbari R, He M and Kebebew E:
CDC23 regulates cancer cell phenotype and is overexpressed in
papillary thyroid cancer. Endocr Relat Cancer. 18:731–742. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li X, Zhong W, Xu Y, Yu B and Liu H:
Silencing of lncRNA LINC00514 inhibits the malignant behaviors of
papillary thyroid cancer through miR-204-3p/CDC23 axis. Biochem
Biophys Res Commun. 508:1145–1148. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Achari C, Winslow S, Ceder Y and Larsson
C: Expression of miR-34c induces G2/M cell cycle arrest in breast
cancer cells. BMC Cancer. 14:5382014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xiong J, Feng Z, Li Z, Zhong T, Yang Z, Tu
Y, Xiao T, Jie Z and Cao Y: Overexpression of TWA1 predicts poor
prognosis in patients with gastric cancer. Pathol Res Pract.
215:1525942019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhuang Y, Li X, Zhan P, Pi G and Wen G:
MMP11 promotes the proliferation and progression of breast cancer
through stabilizing Smad2 protein. Oncol Rep. 45:2021. View Article : Google Scholar
|
|
26
|
Rezaeian AH, Li CF, Wu CY, Zhang X,
Delacerda J, You MJ, Han F, Cai Z, Jeong YS, Jin G, et al: A
hypoxia-responsive TRAF6-ATM-H2AX signalling axis promotes HIF1α
activation, tumorigenesis and metastasis. Nat Cell Biol. 19:38–51.
2017. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Y, Li Z, Fan X, Xiong J, Zhang G,
Luo X, Li K, Jie Z, Cao Y, Huang Z, et al: PRL-3 promotes gastric
cancer peritoneal metastasis via the PI3K/AKT signaling pathway
in vitro and in vivo. Oncol Lett. 15:9069–9074.
2018.PubMed/NCBI
|
|
28
|
Pan G, Liu Y, Shang L, Zhou F and Yang S:
EMT-associated microRNAs and their roles in cancer stemness and
drug resistance. Cancer Commun (Lond). 41:199–217. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Paolillo M and Schinelli S: Extracellular
matrix alterations in metastatic processes. Int J Mol Sci.
20:49472019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao N, Lai F, Fernald AA, Eisenbart JD,
Espinosa R, Wang PW and Le Beau MM: Human CDC23: cDNA cloning,
mapping to 5q31, genomic structure, and evaluation as a candidate
tumor suppressor gene in myeloid leukemias. Genomics. 53:184–190.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Valastyan S and Weinberg RA: Tumor
metastasis: Molecular insights and evolving paradigms. Cell.
147:275–292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mierke CT: The matrix environmental and
cell mechanical properties regulate cell migration and contribute
to the invasive phenotype of cancer cells. Rep Prog Phys.
82:0646022019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yeung KT and Yang J:
Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol.
11:28–39. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pastushenko I and Blanpain C: EMT
transition states during tumor progression and metastasis. Trends
Cell Biol. 29:212–226. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mittal V: Epithelial mesenchymal
transition in tumor metastasis. Annu Rev Pathol. 13:395–412. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pastushenko I, Brisebarre A, Sifrim A,
Fioramonti M, Revenco T, Boumahdi S, Van Keymeulen A, Brown D,
Moers V, Lemaire S, et al: Identification of the tumour transition
states occurring during EMT. Nature. 556:463–468. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang J, Liu D, Feng Z, Mao J, Zhang C, Lu
Y, Li J, Zhang Q, Li Q and Li L: MicroRNA-138 modulates metastasis
and EMT in breast cancer cells by targeting vimentin. Biomed
Pharmacother. 77:135–141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bhandari A, Zheng C, Sindan N, Sindan N,
Quan R, Xia E, Thapa Y, Tamang D, Wang O, Ye X and Huang D: COPB2
is up-regulated in breast cancer and plays a vital role in the
metastasis via N-cadherin and Vimentin. J Cell Mol Med.
23:5235–5245. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Greco A, De Virgilio A, Rizzo MI, Pandolfi
F, Rosati D and de Vincentiis M: The prognostic role of E-cadherin
and β-catenin overexpression in laryngeal squamous cell carcinoma.
Laryngoscope. 126:E148–E155. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nakajima S, Doi R, Toyoda E, Tsuji S, Wada
M, Koizumi M, Tulachan SS, Ito D, Kami K, Mori T, et al: N-cadherin
expression and epithelial-mesenchymal transition in pancreatic
carcinoma. Clin Cancer Res. 10:4125–4133. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen L, Guo P, He Y, Chen Z, Chen L, Luo
Y, Qi L, Liu Y, Wu Q, Cui Y, et al: HCC-derived exosomes elicit HCC
progression and recurrence by epithelial-mesenchymal transition
through MAPK/ERK signalling pathway. Cell Death Dis. 9:5132018.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hashiguchi M, Ueno S, Sakoda M, Iino S,
Hiwatashi K, Minami K, Ando K, Mataki Y, Maemura K, Shinchi H, et
al: Clinical implication of ZEB-1 and E-cadherin expression in
hepatocellular carcinoma (HCC). BMC Cancer. 13:5722013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhai X, Zhu H, Wang W, Zhang S, Zhang Y
and Mao G: Abnormal expression of EMT-related proteins, S100A4,
vimentin and E-cadherin, is correlated with clinicopathological
features and prognosis in HCC. Med Oncol. 31:9702014. View Article : Google Scholar : PubMed/NCBI
|
